| 中文名称 | 双氯芬酸二乙胺 |
| 英文名称 | Diclofenac diethylamine |
| CAS号 | 78213-16-8 |
| 分子式 | C18H22Cl2N2O2 |
| 分子量 | 369.29 |
| EINECS号 | 616-599-2 |
| 熔点 | 145-148°C |
| 溶解度 | DMF:30mg/mL; DMSO:10mg/mL;乙醇:30mg/mL; PBS(pH 7.2):2 mg/mL |
| 形态 | 结晶固体 |
| 颜色 | 白色至米白色 |
| 稳定性 | 吸湿性 |
|
Human COX-2 1.3 nM (IC 50 , in CHO cells) |
Human COX-1 4 nM (IC 50 , in CHO cells) |
Ovine COX-2 0.84 μM (IC 50 ) |
Ovine COX-1 5.1 μM (IC 50 ) |
Diclofenac diethylamine抗炎,退热,和镇痛作用的主要作用机制被认为是通过抑制环氧合酶(COX),从而抑制前列腺素合成。它通过抑制细菌DNA合成发挥出抑菌活性。COX的抑制也会减少胃上皮细胞中的前列腺素,使其对胃酸的腐蚀更敏感。这也是diclofenac diethylamine的主要副作用。Diclofenac diethylamine阻断COX2-同工酶(大约10倍),具有低到中度的选择性,因此,diclofenac diethylamine造成的胃肠疾病的发生率比消炎痛和阿司匹林低。
Diclofenac (3 mg/kg, b.i.d., for 5 days) significantly increases faecal
51
Cr excretion in rats, and such effect is also observed in squirrel monkeys after administrated of 1 mg/kg twice daily for 4 days.
Diclofenac (10 mg/kg; administered via oral route just prior to induction of inflammation) shows in vivo anti-inflammatory activity in Wistar rats.
| Animal Model: | Male Sprague-Dawley rats (150±200 g) |
| Dosage: | 3 mg/kg |
| Administration: | Oral administration, b.i.d., for 5 days |
| Result: | Resulted in a significant increase in faecal 51 Cr excretion. |
| Animal Model: | Wistar rats (150-175 g) bearing Formalin-induced rat foot paw edema model |
| Dosage: | 10 mg/kg |
| Administration: | Administered via oral route just prior to induction of inflammation |
| Result: | Showed in vivo anti-inflammatory activity (% edema inhibition=29.2, 1 h; 22.2, 3 h; 20, 6 h). |